Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Gains from Sales and Divestitures (2021 - 2025)

TELA Bio (TELA) has 5 years of Gains from Sales and Divestitures data on record, last reported at $268601.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 50.19% year-over-year to $268601.0; the TTM value through Sep 2025 reached $268601.0, up 50.19%, while the annual FY2024 figure was $191175.0, 88.24% up from the prior year.
  • Gains from Sales and Divestitures reached $268601.0 in Q3 2025 per TELA's latest filing, up from $231011.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $268601.0 in Q3 2025 and bottomed at $12000.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $108119.5, with a median of $98746.5 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 239.86% in 2022, then skyrocketed 40.61% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $12000.0 in 2021, then skyrocketed by 239.86% to $40783.0 in 2022, then soared by 149.02% to $101559.0 in 2023, then soared by 88.24% to $191175.0 in 2024, then surged by 40.5% to $268601.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $268601.0 in Q3 2025, $231011.0 in Q2 2025, and $198280.0 in Q1 2025.